Clinical trials: Chagas Disease
Chagas Disease
Prospective Study of Benznidazole for Chagas' Disease Children With Chronic Indeterminate Chagas Disease
This study evaluate the efficacy and safety of benznidazole in the treatment of chronic indeterminate Chagas disease in children.
- Trial name
- NCT04024163
- Testing
- Benznidazole
- Where
- 9 sites in Argentina, Bolivia and 1 more
- Volunteers
- 178 people
- Sponsor
- Insud Pharma
Chagas Disease
Shorter Benznidazole Regimens Compared to the Standard Regimen for Chagas Disease
Chagas disease, a parasitic infection caused by Trypanosoma cruzi, is endemic in much of Latin America and affects people throughout the world.
- Trial name
- NuestroBen (NCT04897516)
- Testing
- Short regimen of benznidazole, Short treatment with benznidazole, Standard treatment with benznidazole
- Where
- 6 sites in Argentina
- Volunteers
- 300 people
- Sponsor
- Laboratorio Elea Phoenix S.A.
Chagas Disease
A Study to Learn How Well Nifurtimox Works and How Safe it is in Children Aged 0 to 17 Years With Chagas' Disease, an Inflammatory, Infectious Disease Caused by the Parasite Trypanosoma Cruzi
Researchers are looking for a better way to treat children who have an infectious disease caused by the parasite Trypanosoma cruzi (Chagas' disease).
- Trial name
- NCT02625974
- Testing
- Nifurtimox (Lampit, BAYA2502)
- Where
- 25 sites in Argentina, Bolivia and 1 more
- Volunteers
- 330 people
- Sponsor
- Bayer
Visceral Leishmaniasis, Chagas Disease
A First-in-human, Safety, Tolerability, and Pharmacokinetics Study of LXE408 in Healthy Subjects
The purpose of this first-in-human study is to generate the necessary safety, tolerability, and pharmacokinetics (PK) information that will support further clinical development of LXE408 for the treatment of patients with…
- Trial name
- NCT07809919
- Testing
- LXE408, Iohexol
- Where
- United States
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Chagas Disease
Study to Assess Bioequivalence of 30 and 120 mg Nifurtimox Tablets in Chronic Chagas' Patients
This study will evaluate the bioequivalence as well as safety and tolerability of a novel 30 mg tablet of nifurtimox compared to the corresponding marketed 120 mg tablet in adult subjects suffering from chronic Chagas' disease…
- Trial name
- NCT01927224
- Testing
- Nifurtimox (BAYa2502) (4 x 30 mg tablet), Nifurtimox (BAYa2502) (slurry of 4 x 30 mg tablets in tap water), Nifurtimox (BAYa2502) (120 mg tablet)
- Where
- Argentina
- Volunteers
- 37 people
- Sponsor
- Bayer
Chagas Disease, Heart Failure
Efficacy and Safety of Sacubitril/Valsartan Compared With Enalapril on Morbidity, Mortality, and NT-proBNP Change in Patients With CCC
The purpose of this study was to evaluate the effect of sacubitril/valsartan 200 mg BID compared with enalapril 10 mg BID, in addition to conventional heart failure (HF) treatment, in improving a hierarchical composite of…
- Trial name
- PARACHUTE-HF (NCT04023227)
- Testing
- Sacubitril/valsartan, Enalapril
- Where
- 79 sites in Argentina, Brazil and 2 more
- Volunteers
- 922 people
- Sponsor
- Novartis Pharmaceuticals
Infectious Diseases
Specificity Study of Diagnostic for Chagas Disease
This study assesses the specificity of Chagas Detect™ Plus (CDP) rapid test versus standard reference tests (e.g. RIPA or IFA) for Chagas diagnosis in the US.
- Trial name
- NCT02544139
- Testing
- Chagas Detect Plus
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- InBios International, Inc.
Chagas Disease
A Study of Efficacy, Safety, Tolerability of LXE408 in Participants With Chronic Chagas Disease.
This study is to investigate the ability of LXE408 to clear or reduce the level of parasites in the blood of people with chronic Chagas disease. Participants must have chronic Chagas disease without severe organ dysfunction.
- Trial name
- NCT06632600
- Testing
- LXE408, Benznidazole
- Where
- 22 sites in United States, Argentina and 2 more
- Volunteers
- 130 people
- Sponsor
- Novartis Pharmaceuticals
Chagas Disease
Study to Assess the Food Effect on the Pharmacokinetics of Nifurtimox Tablets in Chronic Chagas' Patients
This study will evaluate the effect of food on the absorption of the drug as well as safety and tolerability of the novel 30 mg tablet (administered as 120 mg dose) in adults suffering from chronic Chagas' disease when…
- Trial name
- NCT02606864
- Testing
- Nifurtimox (BAYa2502)
- Where
- Argentina
- Volunteers
- 36 people
- Sponsor
- Bayer
Healthy Volunteers
First-in-Human Trial of Oral AN2-502998
First-in-Human Phase 1, Single-Center, Randomized, Blinded, Placebo-Controlled Trial in Healthy Adults to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of Oral AN2-502998
- Trial name
- NCT07024589
- Testing
- AN2-502998
- Where
- Australia
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- AN2 Therapeutics, Inc
Chagas Disease, Heart Diseases
Reveal Chagas: Clinical Evidence of the Implantable Cardiac Monitor in Patients With Chagas Disease
The study "Reveal Chagas: Clinical Evidence of the Implantable Cardiac Monitor in Patients with Chagas Disease" is a prospective, multicenter, randomized study that is being conducted at several centers in Latin America with…
- Trial name
- NCT01539161
- Testing
- Implantable Cardiac Monitor, Standard of Care
- Where
- 4 sites in Argentina, Colombia
- Volunteers
- 12 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Chagas Disease
An Observational Pregnancy Safety Study in Women Who Were Exposed to the Drug Nifurtimox During Pregnancy to Learn About the Risk of Pregnancy Complications and About the Mother's and Baby's Health
This is an observational study in which data from women with Chagas disease who will take or have already taken nifurtimox during pregnancy and the impact on their babies are studied.
- Trial name
- NCT05477953
- Testing
- Nifurtimox (BAYA2502)
- Where
- 12 sites in United States, Argentina and 10 more
- Volunteers
- 50 people
- Sponsor
- Bayer
Bioequivalence
Study to Assess Bioequivalence of a New Nifurtimox Oral Tablet Formulation
The primary objective of the current study is to investigate the bioequivalence of a newly developed 120 mg nifurtimox tablet formulation (Test treatment) compared with the 120 mg nifurtimox tablet currently used in the Bayer…
- Trial name
- NCT03708133
- Testing
- Nifurtimox (Lampit, BAYA2502)_Test, Nifurtimox (Lampit, BAYA2502)_Reference
- Where
- Argentina
- Volunteers
- 24 people
- Sponsor
- Bayer
Chagas Disease
Abbott ESA Chagas Assay Post-Market Study
The study is conducted to meet an FDA post market commitment to collect and report data on the performance of the ESA Chagas assay.
- Trial name
- ESA (NCT01662362)
- Testing
- Testing Donor Specimens with ESA Chagas
- Where
- 2 sites in United States
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Abbott Diagnostics Division
Chagas' Disease
Study to Assess the Food Effect on the Pharmacokinetics of Nifurtimox Tablets in Chronic Chagas' Patients - Dietary Habits Study
This study evaluated the effect of food on the absorption of the drug as well as safety and tolerability in adults suffering from chronic Chagas' disease In addition pharmacokinetics of the drug following 120 and 240 mg single…
- Trial name
- NCT03334838
- Testing
- Nifurtimox (Lampit, BAYA2502)
- Where
- Argentina
- Volunteers
- 36 people
- Sponsor
- Bayer
Chagas Disease
Study Will Evaluate the Relative Bioavailability, Safety, and Tolerability of Single Doses of Nifurtimox 30 mg Tablets Exhibiting Different in Vitro Dissolution Characteristics, and to Evaluate the Relative Bioavailability of Nifurtimox 30 mg and 120 mg
Study to assess the relative Bioavailability To assess the relative bioavailability of three formulations of nifurtimox 30 mg tablets exhibiting different in vitro dissolution profiles To assess the pharmacokinetics (PK) of…
- Trial name
- NCT03350295
- Testing
- Nifurtimox (Lampit, BAYA2502)
- Where
- Argentina
- Volunteers
- 48 people
- Sponsor
- Bayer
Chagas Disease
A Study of the Use of Oral Posaconazole (POS) in the Treatment of Asymptomatic Chronic Chagas Disease (P05267)
This is a study to compare the efficacy of oral posaconazole to placebo for the treatment of asymptomatic Chagas disease. The primary hypothesis of the study is that posaconazole 400 mg twice daily improves therapeutic response…
- Trial name
- STOP CHAGAS (NCT01377480)
- Testing
- Posaconazole, Benznidazole
- Volunteers
- 120 people
- Sponsor
- Merck Sharp & Dohme LLC
Chagas' Disease
Study on Benefits of Therapy With Nifurtimox in Chagas Disease, a Parasitic Illness Mostly Transmitted to Humans by a Bug, Using Information From Patient Medical Records in Argentina
The researchers in this trial want to analyze prerecorded patient data which provide information on benefits of the drug nifurtimox in patients with a sudden (acute) and long lasting (chronic) Chagas´ disease an illness caused by…
- Trial name
- NCT03784391
- Testing
- Lampit (Nifurtimox, BAYA2502)
- Where
- Argentina
- Volunteers
- 3,000 people
- Sponsor
- Bayer
Infectious Diseases
Sensitivity Study of Diagnostic for Detection of Chagas Infection
This study is a multi-site trial assessing the sensitivity of Chagas Detect™ Plus rapid test versus standard reference tests (e.g. IFA, IHA, RIPA) for Chagas diagnosis.
- Trial name
- NCT02134548
- Where
- 2 sites in Bolivia, Chile
- Volunteers
- 1,601 people
- Sponsor
- InBios International, Inc.